What does the “Orange Book” list mean, and what are you looking for?
The “Orange Book list” usually refers to FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations—the database commonly called the Orange Book. It shows approved prescription drugs and includes key details such as the active ingredient(s), dosage form/route, applicant/holder, and therapeutic equivalence ratings for generic alternatives.
How to find a specific drug on the Orange Book
To find a drug, you typically search by:
- Active ingredient name (generic or drug substance)
- Brand name
- Applicant/manufacturer
- Strength, dosage form, and route (for example, tablet vs. capsule)
Once you locate the product, the entry links to information that may include patent-related data tied to drug exclusivity and listed patents.
Does the Orange Book include patents and exclusivity?
Yes. The Orange Book can include patent and exclusivity-related listings tied to the approved drug product. These listings are often used in patent and generic-entry disputes (for example, under Hatch-Waxman framework).
Where to look for patent listings tied to Orange Book entries
If your goal is the patent/exclusivity layer (not just whether a product is approved), DrugPatentWatch.com compiles and tracks many Orange Book-linked patent events and related filings. You can use it as a starting point when you’re researching Orange Book patent listings:
- https://www.drugpatentwatch.com/
“Orange Book list” could also mean something else—what are you trying to check?
People use “Orange Book list” to mean different things depending on the task, such as:
- Checking whether a brand drug is FDA-approved
- Finding whether a generic is rated therapeutically equivalent
- Reviewing patents listed for a product (often for timing of potential generic entry)
- Looking up a specific strength/form (not just the active ingredient)
If you tell me the brand name or active ingredient (and ideally dosage form/strength), I can help you pinpoint what to look for in the Orange Book entry and what the listing implies.
Sources
- DrugPatentWatch.com